These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 27246234)

  • 41. Fosfomycin trometamol in the prophylaxis of post-kidney transplant urinary tract infection: A controlled, randomized clinical trial.
    Arreola-Guerra JM; Rosado-Canto R; Alberú J; Maravilla E; Torres-González P; Criollo E; Pérez M; Mancilla E; Arvizu M; Morales-Buenrostro LE; Vilatobá-Chapa M; Sifuentes-Osornio J
    Transpl Infect Dis; 2018 Oct; 20(5):e12980. PubMed ID: 30133928
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Progressive increase of resistance in Enterobacteriaceae urinary isolates from kidney transplant recipients over the past decade: narrowing of the therapeutic options.
    Origüen J; Fernández-Ruiz M; López-Medrano F; Ruiz-Merlo T; González E; Morales JM; Fiorante S; San-Juan R; Villa J; Orellana MÁ; Andrés A; Aguado JM
    Transpl Infect Dis; 2016 Aug; 18(4):575-84. PubMed ID: 27373698
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetic/pharmacodynamic analysis of oral fosfomycin against Enterobacterales, Pseudomonas aeruginosa and Enterococcus spp. in an in vitro bladder infection model: impact on clinical breakpoints.
    Abbott IJ; Mouton JW; Peleg AY; Meletiadis J
    J Antimicrob Chemother; 2021 Nov; 76(12):3201-3211. PubMed ID: 34473271
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Parenteral polymyxin B use in patients with multidrug-resistant gram-negative bacteremia and urinary tract infections: a retrospective case series.
    Pastewski AA; Caruso P; Parris AR; Dizon R; Kopec R; Sharma S; Mayer S; Ghitan M; Chapnick EK
    Ann Pharmacother; 2008 Sep; 42(9):1177-87. PubMed ID: 18664609
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections.
    Pullukcu H; Tasbakan M; Sipahi OR; Yamazhan T; Aydemir S; Ulusoy S
    Int J Antimicrob Agents; 2007 Jan; 29(1):62-5. PubMed ID: 17189097
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Activity of Fosfomycin against Extended-Spectrum-β-Lactamase-Producing Uropathogens in Patients in the Community and Hospitalized Patients.
    Linsenmeyer K; Strymish J; Weir S; Berg G; Brecher S; Gupta K
    Antimicrob Agents Chemother; 2016 Feb; 60(2):1134-6. PubMed ID: 26596940
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Rodríguez-Baño J; Alcalá JC; Cisneros JM; Grill F; Oliver A; Horcajada JP; Tórtola T; Mirelis B; Navarro G; Cuenca M; Esteve M; Peña C; Llanos AC; Cantón R; Pascual A
    Arch Intern Med; 2008 Sep; 168(17):1897-902. PubMed ID: 18809817
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Oral fosfomycin for treating lower urinary tract infections due to multidrug-resistant
    Polat M; Ozkaya-Parlakay A; Tapısız A; Kara SS; Yüksel S
    J Chemother; 2022 Apr; 34(2):97-102. PubMed ID: 34286658
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Evaluation of the antimicrobial susceptibility of community-acquired urinary tract infection].
    Passadouro R; Fonseca R; Figueiredo F; Lopes A; Fernandes C
    Acta Med Port; 2014; 27(6):737-42. PubMed ID: 25641289
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New ways of using old antibiotics in pediatrics: Focus on fosfomycin.
    Tran MT
    Pharmacotherapy; 2023 Jul; 43(7):705-712. PubMed ID: 36825460
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fosfomycin Susceptibility in Urinary Tract Enterobacteriaceae.
    Patel B; Patel K; Shetty A; Soman R; Rodrigues C
    J Assoc Physicians India; 2017 Sep; 65(9):14-16. PubMed ID: 29313570
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1993). II. Background of patients].
    Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Tazaki H; Iri H
    Jpn J Antibiot; 1995 Nov; 48(11):1788-801. PubMed ID: 8558758
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vitro activity of fosfomycin trometamol against pathogens from urinary tract infections: a Spanish multicenter study.
    García-Rodríguez JA; Trujillano Martín I; Baquero F; Cisterna R; Gobernado M; Liñares F; Martín-Luengo F; Piédrola G
    J Chemother; 1997 Dec; 9(6):394-402. PubMed ID: 9491838
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fosfomycin in treatment of chronic urinary tract infection.
    Gobernado M; Oleza J; Santos M; Roman J; Paz M; Mascaros E; Almela J
    Chemotherapy; 1975; 21(2):99-107. PubMed ID: 1157571
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Oral fosfomycin for the treatment of lower urinary tract infections among kidney transplant recipients-Results of a Spanish multicenter cohort.
    López-Medrano F; Silva JT; Fernández-Ruiz M; Vidal E; Origüen J; Calvo-Cano A; Luna-Huerta E; Merino E; Hernández D; Jironda-Gallegos C; Escudero R; Gioia F; Moreno A; Roca C; Cordero E; Janeiro D; Sánchez-Sobrino B; Montero MM; Redondo D; Candel FJ; Pérez-Flores I; Armiñanzas C; González-Rico C; Fariñas MC; Rodrigo E; Loeches B; López-Oliva MO; Montejo M; Lauzurica R; Horcajada JP; Pascual J; Andrés A; Aguado JM;
    Am J Transplant; 2020 Feb; 20(2):451-462. PubMed ID: 31550408
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Urinary tract infection in male general practice patients: uropathogens and antibiotic susceptibility.
    Koeijers JJ; Verbon A; Kessels AG; Bartelds A; Donkers G; Nys S; Stobberingh EE
    Urology; 2010 Aug; 76(2):336-40. PubMed ID: 20494416
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1992). II. Background of patients].
    Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Ogata M; Tazaki H
    Jpn J Antibiot; 1995 Nov; 48(11):1658-70. PubMed ID: 8558755
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections: A Randomized Clinical Trial.
    Sojo-Dorado J; López-Hernández I; Rosso-Fernandez C; Morales IM; Palacios-Baena ZR; Hernández-Torres A; Merino de Lucas E; Escolà-Vergé L; Bereciartua E; García-Vázquez E; Pintado V; Boix-Palop L; Natera-Kindelán C; Sorlí L; Borrell N; Giner-Oncina L; Amador-Prous C; Shaw E; Jover-Saenz A; Molina J; Martínez-Alvarez RM; Dueñas CJ; Calvo-Montes J; Silva JT; Cárdenes MA; Lecuona M; Pomar V; Valiente de Santis L; Yagüe-Guirao G; Lobo-Acosta MA; Merino-Bohórquez V; Pascual A; Rodríguez-Baño J;
    JAMA Netw Open; 2022 Jan; 5(1):e2137277. PubMed ID: 35024838
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Clinical experience with fosfomycin in urinary tract infections (author's transl)].
    Peters HJ; Eicher R
    MMW Munch Med Wochenschr; 1981 May; 123(18):748-50. PubMed ID: 6785627
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Urinary tract infections in older adults: Etiology and antimicrobial susceptibilities in a southern area of Spain].
    Escandell Rico FM; Pérez Fernández L
    Rev Esp Geriatr Gerontol; 2023; 58(1):22-26. PubMed ID: 36707356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.